and017
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jul 16, 2018 (NCT04751539)
Timeline
Indications
Mechanism of action
- Egl nine homolog 1INHIBITOR
EGLN1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06304103 | Phase 2 | Dec 31, 2024 | Kind Pharmaceuticals LLC |
| NCT06302491 | Phase 2 | May 27, 2024 | Kind Pharmaceuticals LLC |
| NCT06075030 | Phase 2 | Dec 31, 2023 | Kind Pharmaceuticals LLC |
| NCT06075043 | Phase 2 | Dec 31, 2023 | Kind Pharmaceuticals LLC |
| NCT05265325 | Phase 2 | Jan 31, 2023 | Kind Pharmaceuticals LLC |
| NCT05035641 | Phase 2 | Aug 16, 2021 | Kind Pharmaceuticals LLC |
| NCT04712500 | Phase 1 | Jul 30, 2020 | Kind Pharmaceuticals LLC |
| NCT04751539 | Phase 1 | Jul 16, 2018 | Kind Pharmaceuticals LLC |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kind Pharmaceuticals LLC | For profit | 8 | 8 | 2 | 2018 |
1 organizations
Page 1 / 1